280 related articles for article (PubMed ID: 35449080)
1. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1.
Li X; Li J; Xu L; Wei W; Cheng A; Zhang L; Zhang M; Wu G; Cai C
J Exp Clin Cancer Res; 2022 Apr; 41(1):149. PubMed ID: 35449080
[TBL] [Abstract][Full Text] [Related]
2. Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex.
Hernández-Ortega S; Sánchez-Botet A; Quandt E; Masip N; Gasa L; Verde G; Jiménez J; Levin RS; Rutaganira FU; Burlingame AL; Wolfgeher D; Ribeiro MPC; Kron SJ; Shokat KM; Clotet J
Exp Mol Med; 2019 Apr; 51(4):1-17. PubMed ID: 30992425
[TBL] [Abstract][Full Text] [Related]
3. Hsa_circRNA_102229 facilitates the progression of triple-negative breast cancer via regulating the miR-152-3p/PFTK1 pathway.
Du C; Zhang J; Zhang L; Zhang Y; Wang Y; Li J
J Gene Med; 2021 Sep; 23(9):e3365. PubMed ID: 34031947
[TBL] [Abstract][Full Text] [Related]
4. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis.
Mikolcevic P; Sigl R; Rauch V; Hess MW; Pfaller K; Barisic M; Pelliniemi LJ; Boesl M; Geley S
Mol Cell Biol; 2012 Feb; 32(4):868-79. PubMed ID: 22184064
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
7. The Suppressive Effect of Rebastinib on Triple-negative Breast Cancer Tumors Involves Multiple Mechanisms of Action.
Feng K; Jian C; Xiao H; Jiang H; Yang J; Yang M; Sun A; Song W; Chestkov AV; Vasilevich NI; Sun L
Anticancer Res; 2023 Jun; 43(6):2609-2624. PubMed ID: 37247937
[TBL] [Abstract][Full Text] [Related]
8. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
9. The roles, molecular interactions, and therapeutic value of CDK16 in human cancers.
Wang X; Liu R; Li S; Xia W; Guo H; Yao W; Liang X; Lu Y; Zhang H
Biomed Pharmacother; 2023 Aug; 164():114929. PubMed ID: 37236028
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
11. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
12. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
13. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
14. MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression.
Kuo WH; Chu PY; Wang CC; Huang PS; Chan SH
Biol Direct; 2023 Aug; 18(1):44. PubMed ID: 37550720
[TBL] [Abstract][Full Text] [Related]
15. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
18. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
19. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
20. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
